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Introduction
Breast cancer is the most frequently diagnosed cancer in 
women [1]. Breast cancer is the leading cause of cancer 
mortality in women worldwide resulting in more than 
500,000 deaths. Estrogen receptor alpha (ERα) plays an 
important role in mammal normal physiological functions 
and is also intensively related to pathogenesis of breast 
cancer [2]. ERα expression defines a subset of cancer 
patients who, in general, have a better prognosis than 
patients with ERα- negative tumor [3, 4].
Estrogen receptor is considered as an important thera-
peutic target as positive ER expression defines better 
prognosis in patients with breast cancer. ER is a 
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Abstract
FOXC1 is a member of Forkhead box transcription factors that participates in 
embryonic development and tumorigenesis. Our previous study demonstrated 
that FOXC1 was highly expressed in triple- negative breast cancer. However, it 
remains unclear what is the relation between FOXC1 and ERα and if FOXC1 
regulates expression of ERα. To explore relation between FOXC1 and ERα and 
discover regulation of ERα expression by FOXC1 in breast cancer, we analyzed 
data assembled in the Oncomine and TCGA, and found that there was signifi-
cantly higher FOXC1 expression in estrogen receptor- negative breast cancer 
than that in estrogen receptor- positive breast cancer. Overexpression of FOXC1 
reduced expression of ERα and cellular responses to estradiol (E2) and tamoxifen 
in the MCF- 7 FOXC1 and T47D FOXC1 cells, while knockdown of FOXC1 
induced expression of ERα and improved responses to estradiol (E2) and 
 tamoxifen in BT549 FOXC1 shRNA and HCC1806 FOXC1 shRNA cells. In 
addition, overexpression of FOXC1 reduced expression of progesterone receptor 
(PR), Insulin receptor substrate 1 (IRS1), and XBP1 (X- Box Binding Protein 
1) and significantly reduced luciferase activity caused by E2 using ERE luciferase 
reporter assay. These results suggested that FOXC1 regulated expression of ERα 
and affected sensitivity of tamoxifen treatment in breast cancer, and that FOXC1 
may be used as a potential therapeutic target in ERα- negative breast cancer.
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ligand- inducible transcription factor that belongs to the 
nuclear receptor superfamily and a key regulatory molecule 
in mammary epithelial cell development. Recently, a lot 
of researches were focused on regulation of ERα [5, 6]. 
Microarray analyses and experiments have revealed that 
expression of forkhead box A1 (FOXA1) and GATA- binding 
protein 3 (GATA- 3) are closely associated with ERα and 
they encode transcription factors which potentially involve 
in the ERα- mediated action in breast cancer [7, 8].
FOX (Forkhead box) proteins are a family of transcription 
factors that play important roles in regulating the expression 
of genes involved in cell growth, proliferation, differentiation, 
and longevity. Many FOX proteins are important to embry-
onic development and play important roles in tumorigenesis 
[9]. Recently, roles of FOX proteins in breast cancer attracted 
more and more attention. FOXC2 was correlated with human 
breast cancers and played a critical role in promoting inva-
sion and metastasis [10]. FOXA1 was a marker of luminal 
cells in mammary [11, 12]. Downregulation of FOXM1 led 
to inhibition of proliferation, migration, and invasion of 
breast cancer cells through the modulation of extracellular 
matrix degrading factors [13, 14]. Basal- like breast cancers 
(BLBCs) underexpress estrogen receptor (ER), progesterone 
receptor (PR), and human epidermal growth factor receptor 
2 (HER2) and encompass 60–90% of triple- negative (ER−/
PR−/HER2−) breast cancers. Our previous results showed 
that FOXC1 was the only gene overexpressed in BLBC con-
sistently and exclusively, associated with poor overall survival. 
However, it remains unclear what relation between FOXC1 
and ERα is and if FOXC1 regulates expression of ERα [15].
In this study, we performed silicon analysis using data-
base from Oncomine (www.oncomine.org) and TCGA (The 
Cancer Genome Atlas) database, and showed that FOXC1 
expression was higher in ERα- negative breast cancers than 
ERα- positive breast cancers. In addition, overexpression 
of FOXC1 reduced expression of PR, IRS1, and XBP1 
(downstream target of ERα) and significantly reduced 
luciferase activity caused by E2 using ERE luciferase reporter 
assay. FOXC1 expression reduced stimulatory growth effect 
by E2 and inhibited sensitivity of cells to treatment of 
tamoxifen. All results indicated that FOXC1 regulated 
expression of ERα and affected sensitivity of tamoxifen 
treatment in breast cancer, and that FOXC1 may be used 




Human breast cancer cell lines (MCF- 7, T47D, BT549, 
and HCC1806) were purchased from the American Type 
Culture Collection (ATCC) and the cells were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supple-
mented with 10% fetal calf serum, 100U/mL penicillin, 
and 100 μg/mL streptomycin at 37°C humidified incubator 
containing 5% CO2. Human primary breast cancer cell 
lines were obtained from Peking Union Medical College 
Hospital.
Tumor specimens
Approval for the use of human tissues was approved by 
the Institutional Review Board (IRB) at the Peking Union 
Medical College Hospital, Beijing, China. Analysis was 
conducted on paraffin- embedded archival tissue (PEAT) 
specimens of breast cancer diagnosed at the Peking Union 
Medical College Hospital.
Stable transfection
MCF- 7 and T47D cells were plated in 60- mm dishes at 
80% confluence before 24 h of transfection. FOXC1–myc–
flag plasmid was transfected into the MCF- 7 and T47D 
cells using Lipofectamine™ 3000 Transfection reagent 
(Invitrogen, Grand Island, NY) for 24 h. The cells were 
then screened under 0.8 mg/mL G418 (Invitrogen) for 
3 weeks. MCF- 7 and T47D cells with overexpressing FOXC1 
were subcloned as MCF- 7- FOXC1 and T47D- FOXC1, 
respectively [16].
BT549 and HCC1806 cells were plated in 60 mm dishes 
at 80% confluence before 24 h of transfection. FOXC1 
shRNAs (Sigma- Aldrich, St. Louis, MO) were stably trans-
fected into BT549 and HCC1806 cells which have high 
FOXC1 expression and were selected in 5 μg/mL puro-
mycin. BT549 and HCC1806 cells which have low FOXC1 
expression were subcloned as BT549 FOXC1 shRNA and 
HCC1806 FOXC1 shRNA, respectively.
Expression of FOXC1 was verified by Western blot 
analysis with anti- FOXC1 antibody (Cata No. sc21394, 
Santa Cruz Biotechnology, Santa Cruz, CA), antimyc anti-
body (Cata No. 06- 340; EMD Millipore, San Diego, CA), 
and antiflag antibody (Cata No. TA50011- 100, Origene, 
Rockville, MD).
Transient transfection assay
Cells were plated in 60 mm dishes at 80% confluence 
before 24 h of transfection. The FOXC1–myc–flag plasmid 
and promoter luciferase (ERE- Luc) were transfected into 
MCF- 7 cells using Lipofectamine™ 3000 Transfection rea-
gent (Invitrogen) [17]. FOXC1–myc–flag plasmid (500 ng), 
Renilla (50 ng), and luciferase reporter construct (100 ng) 
were transfected into the cells in 6- well plate. Renilla 
expression vector was cotransfected as an internal control. 
After transfected for 24–36 h, cells were washed twice 
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with PBS buffer and harvested in 200 μL of 1× reporter 
lysis buffer (Promega, Madison, WI). Cell lysis was cen-
trifuged at 12,000 g for 10 min at 4°C and supernatant 
was collected. Cell extract (20 μL) was mixed with 100 μL 
Luciferase Assay Reagent (Promega, Madison, WI) at room 
temperature and immediately placed in GloMax® —Multi 
diction system (Promega).
Immunoblot analysis
Whole cell extracts were prepared from MCF- 7 vector 
and MCF- 7- FOXC1, T47D vector and T47D- FOXC1, 
BT549 vector and BT549 FOXC1 shRNA, and HCC1806 
vector and HCC1806 FOXC1 shRNA cells. Western blot 
assays were done as previously described [18]. 
Immunoblotting was done with polyclonal antibodies 
against FOXC1, IRS1 (insulin receptor substrate 1) (1:200; 
Cata No. sc7200, Santa Cruz Biotechnology), monoclonal 
antibodies against ERα (1:500, Cata No. 8644, Cell 
Signaling, Danvers, MA), PR (progesterone receptor) 
(1:500; Clone PgR 363, Dako, Carpinteria, CA), and XBP1 
(Cata No, SAB2102720; Sigma- Aldrich). Anti- β actin (Cata 
No.A5316; Sigma- Aldrich) was used at a 1:10000 dilution. 
Incubation with primary antibodies overnight was followed 
by incubation with secondary antibody (1:4000; Anti- mouse 
IgG NA931V, Anti- rabbit IgG NA934V GE Biosciences 
and 1:4000, Anti- goat IgG, Cata No. sc2020, 
Biotechnology). Detection was carried out using the Pierce 
SuperSignal West Pico chemiluminescent substrate 
(Thermo fisher, Rockford, lL) followed by scanning using 
a Fluorchem 5500 chemiluminescence imager (Alpha 
Innotech Corp, San Leandro, CA).
Real- time reverse transcription PCR
Total RNA was isolated from MCF- 7 vector and MCF- 
7- FOXC1, T47D vector and T47D–FOXC1 cells, BT549 
vector and BT549 FOXC1 shRNA, and HCC1806 vector 
and HCC1806 FOXC1 shRNA using RNeasy mini kit 
(Qiagen, Hilden, Germany), with on- column DNase treat-
ment to remove contaminating genomic DNA. Real- time 
reverse transcription PCR (RT- PCR) was done as in 
reference [19]. The primers (Integrated DNA 
Technologies, Inc., Coralville, IA) for RT- PCR were listed 
in Table S1.
Immunocytofluorescence assay
MCF- 7 cells were transiently transfected with FOXC1- GFP 
plasmid. After transfected for 24 h, the cells were digested 
with trypsin and mixed with untransfected MCF- 7 cells. 
The mixed cells were cultured in chamber slides (Nunc 
Lab- Tek, St. Louis, MO). Cells were fixed with 4% 
formaldehyde and then permeabilized with PBS containing 
0.1% Triton X- 100. Slides were blocked by 5% BSA for 
30 min and incubated with a primary antibody (Cata 
No. 8644, anti–ERα antibody, 1:100, Cell Signaling, 
Danvers, MA) at room temperature for 1 h. Then, cells 
were incubated with an Alexa 546–conjugated secondary 
antibody (Cata No. A- 11030, 1:500, Invitrogen, Grand 
Island, NY) for 30 min. Slides were washed by PBS three 
times, 5 min each time, mounted with DAPI (Vector 
Laboratories, Burlingame, CA), and observed under Nikon 
microscope (Nikon, Melville, NY) [20].
Cell proliferation assay
The Promega CellTiter 96® AQueous One Solution Cell 
Proliferation Assay was used according to the manufac-
turer’s instructions (Promega, Madison, WI). Cells were 
seeded into 96- well plates (1000 cells per well) in triplicate. 
Absorbance at 490 nm was measured after the addition 
of 20 μL of MTS reagent per well for 2 h, every 24 h 
over a 96 h period [21, 22].
Immunohistochemistry
Five- micrometer paraffin- embedded tissue sections were 
deparaffinized and rehydrated, antigens were retrieved, and 
IHC was performed using an optimized protocol [23, 24]. 
Slides were deparaffinized, rehydrated, and washed in 1X 
PBS. Antigen retrieval was performed with 1X citrate buffer 
(Sigma- Aldrich) at 100°C for 10 min and then incubated 
in H2O2 (Sigma- Aldrich) at room temperature to block 
endogenous peroxidase. Separate slides were incubated in 
primary rabbit Anti- FOXC1 antibody (aa250- 300) IHC- 
plus™ LS- B1800 (1:250 dilution; Seattle, WA) overnight 
in a 4°C humid chamber followed by 1 h incubation 
with secondary biotinylated link Ab. The reaction for 
FOXC1 was developed using a labeled streptavidin biotin 
(LSAB) method (LSAB+ Kit; Dako, Carpinteria, CA) and 
visualized using VIP Substrate Kit (Vector Laboratories, 
Burlingame, CA). Specificity of the immunostaining was 
determined by the inclusion of isotype- specific IgG (Santa 
Cruz Biotechnology, Santa Cruz, CA) as negative controls. 
The sections were counterstained with hematoxylin (Sigma- 
Aldrich). A photograph of each IHC- stained section was 
taken for analysis using a Nikon Eclipse Ti microscope 
and NIS elements software (Nikon, Melville, NY). Staining 
density was determined by Image J software (http://rsbweb.
nih.gov/ij/). After adjustment for background on each 
selected field, the density of the individual breast cancer 
specimen was quantified and given a numerical value from 
0 to 255. Breast cancer specimens were tested in duplicate, 
and the average of the two staining intensity values was 
used for statistical analysis.
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Nude mice for xenograft assays
Twelve nude mice (BALB/c background) (experimental 
animal center, Chinese Academy of Sciences, Shanghai, 
China) were randomly divided into two groups and housed 
in air conditioned, light- controlled, animal facilities. Animal 
care and all experiments were in accordance with the 
institutional guidelines and were approved by the Animal 
Care and Use Committee in accordance with regulations 
of Institutional Animal Care and Use Committee. To test 
the tumorigenic properties of cells, MCF- 7 vector and 
MCF- 7 FOXC1 (1 × 106) cells were orthotopically injected 
into the number four mammary fat pads of female nude- 
BALB/c mice (6 mice for each cell line) [25].
Mice were weighed and subcutaneous tumors were meas-
ured after a week; tumor volume was obtained by the 
ellipsoid volume calculation formula: 0.5× (length × width2).
Statistical analysis
The results are given as mean ± SD of samples measured 
in triplicate. Each experiment was repeated three times, 
unless otherwise indicated. Student’s t- test was used to 
calculate differences between the various study groups. 
The difference was considered statistically significant at 
P < 0.05.
Results
FOXC1 is negatively correlated with luminal 
expression signatures: ESR1, FOXA1, GATA3, 
XBP1, and MYB
Our previous study showed that FOXC1 was highly 
expressed in triple- negative breast cancer. However, the 
mechanism remains unclear. To explore the mechanism, 
silicon assay was performed using TCGA database (http://
www.cbioportal.org/public-portal/cross_cancer.do). Results 
showed that expression of FOXC1 mRNA was negatively 
correlated with luminal expression signatures: ESR1, 
FOXA1, GATA3, XBP1, and MYB expression (Fig. 1A–E). 
We also found that FOXC1 was amplified in invasive breast 
cancer (8%) (Fig. S1).
Figure 1. FOXC1 is negatively correlated with luminal expression signatures. (A) FOXC1 is negatively correlated with ESR1. (B) FOXC1 is negatively 
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FOXC1is highly expressed in ERα- negative 
breast cancer
Basal- like breast cancers are characterized by high expression 
of basal cytokeratins, low or absent expression of estrogen 
receptor, progesterone receptor, and HER2. Our previous 
study showed that there was high FOXC1 expression in 
basal- like breast cancers (no or very low ERαα expression). 
To confirm the relation between FOXC1 expression levels 
and ERα status of breast cancer, we compared the expres-
sion levels of FOXC1 in the ERα- negative and - positive 
breast cancer using the Oncomine and TCGA (The Cancer 
Genome Atlas) database, which provides publicly available 
datasets on cancer gene expression. Eleven of the 11 datasets 
from Oncomine, which contain gene chip profiles classified 
as normal or breast carcinoma tissues, showed that FOXC1 
mRNA levels were much higher in ERα- negative breast 
cancers than that in ERα- positive breast cancers (Fig. 2 
and S2). TCGA data also confirmed the result (Fig. S3).
FOXC1 reduced expressions of ERα and its 
downstream targets
FOXC1 is the only gene to be consistently and exclusively 
overexpressed in BLBC and is associated with poor overall 
Figure 2. FOXC1 expression is negatively related with ERα expression. (A–F) There was higher FOXC1 expression in ERα- negative tumors than that in 
ERα- positive tumors. Data and statistics were obtained from www.oncomine.org (Richardon et al., 2006; Sorlie et al., 2001; Zhao et al., 2004; Bittner 
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survival (P = 0.0001) (11). To test whether FOXC1 affects 
ERα gene expression, MCF- 7 and T47D were transfected 
with FOXC1–myc–flag plasmid, and the stable clones were 
obtained. All these clones were pooled. We carried out 
real- time PCR and Western blot assay by using the MCF- 7 
vector and MCF- 7- FOXC1, T47D vector and T47D- FOXC1. 
There is much lower ERα mRNA and protein expression 
in the MCF- 7- FOXC1 and T47D- FOXC1 cells than that 
in the MCF- 7 vector and T47D vector, respectively. 
(Fig. 3A–C and S4).
To investigate functional effects of the downregulation 
of ERα by FOXC1, expression of XBP1, PR, and IRS1 
was evaluated as downstream targets of ERα using Western 
blot. Expression of XBP1, PR, and IRS1 was decreased 
in the MCF- 7- FOXC1 and T47D- FOXC1 cells compared 
to MCF- 7 vector and T47D vector, respectively (Fig. 3D 
and S5A).
In immunocytofluorescence assay, it was showed in 
Figure 3E that there is much lower ERα expression in 
transiently transfected MCF- 7 cells with FOXC1–EGFP 
(Enhanced Green Fluorescent Protein) plasmid than MCF- 7 
vector cells. Luciferase reporter plasmids- containing EREs 
were transfected into MCF- 7 cells with or without FOXC1–
myc–flag. Estrogen treatment enhanced the transcription 
of these reporter plasmids. The estrogen- stimulated 
enhanced transcription was inhibited by FOXC1 expression 
(Fig. 3F).
Meanwhile, BT549 and HCC1806 cell lines which have 
high FOXC1expression were transfected by FOXC1 
shRNA and the stable clones were obtained. Expression 
Figure 3. FOXC1 reduced expression of ERα and its downstream targets. (A) ERα mRNA expression was decreased when FOXC1 mRNA expression 
was increased. (B) Quantification of FOXC1 mRNA expression in MCF- 7 vector and MCF-7-FOXC1. (C) Quantification of ERα mRNA expression in 
MCF- 7 vector and MCF- 7-FOXC1. (D) Protein expression of PR, IRS- 1, and XBP1 (downstream target of ERα) was decreased when FOXC1 protein 
expression was increased. (E) There is almost no ERα expression in cells which have high FOXC1 expression level (green color) transfected by FOXC1 
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of FGF19 (downstream target FOXC1), ERα and XBP1 
(downstream target of ERα) was checked in these clones 
using Western blot. Results showed that mRNA 
expression of ERα was increased when mRNA expres-
sion of FOXC1 was reduced by FOXC1 shRNA (Figs. 4A, 
B and S6A, B). Expression of ERα and XBP1 was 
Figure 4. Kncokdown of FOXC1 induced expression of ERα. (A) Expression of FOXC1 mRNA was significantly reduced by two- pair FOXC1 shRNAs in 
BT549 FOXC1 shRNA. (B) Expression of ERα mRNA was induced when expression of FOXC1 was reduced in BT549 FOXC1 shRNA. (C) Protein 
expression of ERα and XBP1 (downstream target of ERα) was increased while protein expression of FOXC1 and FGF19 (downstream target of FOXC1) 
was reduced in BT549 FOXC1 shRNA. (D) FOXC1 shRNA can activate ERE- luc luciferase.
A B
DC
Figure 5. FOXC1 reduced cell response to estrogen and tamoxifen. (A) Growth of MCF- 7- FOXC1 was not more sensitive to E2 than that of MCF- 7 
vector. (B) MCF- 7- FOXC1 was not more sensitive to treatment of tamoxifen than MCF- 7 vector. (C) Growth of BT549 FOXC1 shRNA was more 
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increased when expression of FOXC1 and FGF19 was 
reduced in BT549 FOXC1 shRNA and HCC1806 FOXC1 
shRNA (Fig. 4C, S6C). FOXC1 shRNA activated ERE- luc 
activity in BT549 and HCC1806 cell lines (Figs. 4D 
and S6D).
Taken together, these results showed that FOXC1 regu-
lated the expression of ERα
FOXC1 reduced cell response to estrogen 
and tamoxifen
ERα belongs to the steroid hormone receptor superfamily 
and functions as a ligand- activated transcription factor. 
ERα is a key player in estrogen- mediated proliferation, 
survival, and differentiation through regulating the tran-
scription of estrogen- target genes as well as through acti-
vation of signal transduction pathways [26].
To investigate the relation between FOXC1 and ERα 
in the growth of breast cancer cells, MCF- 7 vector and 
MCF- 7- FOXC1, T47D vector and T47D- FOXC1, BT549 
vector and BT549 FOXC1 shRNA, HCC1806 vector and 
HCC1806 FOXC1 shRNA cells were cultured in DMEM 
(without phenol red) with E2 or normal culture medium. 
FOXC1 expression reduced stimulatory growth effect by 
E2 in MCF- 7- FOXC1 and T47D- FOXC1 compared to 
MCF- 7 vector and T47D vector in DMEM (without phenol 
red) with E2, respectively, while the growth of BT549 
FOXC1 shRNA and HCC1806 FOXC1 shRNA cells was 
higher than BT549 vector and HCC1806 vector in DMEM 
(without phenol red) with E2, respectively. (Figs. 5A, C 
and S7A, C).
To explore whether the FOXC1 renders resistance to 
the tamoxifen in cells, MCF- 7 vector, MCF- 7- FOXC1, T47D 
vector, and T47D- FOXC1 cells were cultured in DMEM 
(without phenol red) with tamoxifen. As shown in 
Figures 5B and S7B, MCF- 7- FOXC1 and T47D- FOXC1 
cells became more resistant to tamoxifen than control 
cells.
We also check sensitivity of tamoxifen treatment in 
BT549 FOXC1 shRNA and HCC1806 FOXC1 shRNA and 
found that BT549 FOXC1 shRNA and HCC1806 FOXC1 
shRNA cells were more sensitive to tamoxifen than BT549 
Figure 6. FOXC1 was highly overexpressed in ERα- negative breast cancer cell lines. (A) FOXC1 expression was much higher in ERα- negative primary 
breast cell lines (AM70, AM72, AM88, and AN2) than that in ERα- positive primary breast cell lines (AM74, AM86, AM9,2 and AM98). (B–C) FOXC1 
expression in triple- negative breast cancer cells was significantly higher than that in HER 2- positive or luminal (ERα- positive) breast cancer cell lines. 
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vector and HCC1806 vector cells, respectively (Figs. 5D 
and S7D).
FOXC1 was overexpressed in ERα- negative 
breast cancer cell lines
To check if FOXC1 expression is related with status of 
ERα in breast cancer cell lines, Western blot was per-
formed using cell lysis from cell lines of primary breast 
cancers. FOXC1 expression was much higher in ER- 
negative cell lines than that in ER- positive cell lines 
(Fig. 6A). Silicon assay (http://co.bmc.lu.se/gobo/) showed 
that FOXC1 expression in triple- negative cells was sig-
nificantly higher than that in HER 2- positive and luminal 
cell lines (Figs. 6B, C and S8). All results suggested that 
FOXC1 was overexpressed in ERα- negative breast cancer 
cell lines.
FOXC1 was overexpressed in tissues of 
ERα- negative breast cancer
To check FOXC1 expression in breast cancer, we firstly 
analyzed the GOBO online database (http://co.bmc.lu.se/
gobo/), which consists of 10 breast cancer cohorts and 
1789 patients. It was shown in Figure 7A–E that expres-
sion of FOXC1 in basal- like breast cancer was higher 
than other type breast cancer. Data also showed that there 
was higher FOXC1 expression in ERα- negative tumor 
than that in ERα- positive tumor (Fig.  9). Expression of 
FOXC1 was increased with progress of breast cancer 
(Fig. 7F and S10). Secondly, Immunohistochemistry (IHC) 
was done to assess the expression of protein in tissues 
of human breast cancer. The representative pictures were 
shown in Figure 8 A and B. Results from IHC showed 
there was a significantly higher FOXC1 expression in 
Figure 7. FOXC1 mRNA was overexpressed in tissues of ERα- negative breast cancer breast cancer. (A–E) Expression of FOXC1 in basal- like breast 
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Figure 8. FOXC1 protein was overexpressed in tissues of ERα- negative breast cancer. (A) The representative photographs were shown; negative 
control (Left), positive (Right). (B) IHC results showed a significantly higher FOXC1 expression in triple- negative breast cancer (N = 53) compared to 
luminal breast cancer (N = 19). (C) The patients with high FOXC1 expression have the lowest survival rate.
A B
C D
Figure 9. Growth of tumor xenografts in nude mice: comparison of MCF- 7 vector and MCF- 7- FOXC1. (A) Tumor xenografts in MCF- 7- FOXC1 
group are larger than that in MCF- 7 vector group. (B) Representative IHC photographs of FOXC1 expression in xenograft tumor. (C) Growth 
curve of xenograft tumors in MCF- 7- FOXC1 group and MCF- 7 vector group. Growth of xenograft tumors from MCF- 7- FOXC1 cells is higher 
than that of xenograft tumors form MCF- 7 vector cells. (D) Volume of xenograft tumor in MCF- 7- FOXC1 group and MCF- 7 vector group. 
Volume of xenograft tumor in MCF- 7- FOXC1 group is more than that in MCF- 7- FOXC1 vector group. (E) Final weight of xenograft tumors in 
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triple- negative breast cancer compared to luminal breast 
cancer (Fig. 8C).
To assess the clinical significance of FOXC1 in breast 
cancer, Kaplan–Meier meta- analyses were performed using 
the GOBO online database (http://co.bmc.lu.se/gobo). 
Patients with high FOXC1 expression have the lowest 
survival rate (Fig. 8D). These findings support the notion 
that FOXC1 plays a major role in the progression of 
breast cancer metastasis.
FOXC1 enhanced growth of xenograft 
tumors in nude mice
To assess whether FOXC1 increased the tumorigenic prop-
erties of breast cancer cell lines, MCF- 7 vector and MCF- 
7- FOXC1 cells were orthotopically injected into the number 
four mammary fat pads of female nude- BALB/c mice (6 
mice/cell line). Growth and size of tumor were significantly 
increased in MCF- 7- FOXC1 compared to MCF- 7 vector 
(Fig. 9A). Expression of FOXC1 increased the volume and 
weight of tumors (Fig. 9B–E). In summary, FOXC1 increased 
the tumorigenic properties of breast cancer cell lines.
Discussion
FOX (Forkhead box) proteins are a kind of important tran-
scription factors which regulate the expression of genes related 
to cell growth, proliferation, differentiation, and longevity 
[27]. Many FOX proteins are important to embryonic devel-
opment. FOXC1, a member of Forkhead box transcription 
factors essential for mesoderm tissue development in ver-
tebrates [28, 29], consistently showed the highest correlation 
with the basal- like subtype compared to other subtypes in 
the breast cancer. In this study, we found that there was 
significantly higher FOXC1 expression in ERα- negative breast 
cancer and ERα- positive breast cancer. Overexpression 
FOXC1 decreased expression of ERα protein and reduced 
cellular responses to estradiol and tamoxifen, while knock-
down of FOXC1 induced expression of ERα protein and 
improved cellular responses to estradiol and tamoxifen.
ERα positivity was associated with significantly better 
survival than patients with ERα- negative tumors, which 
are widely believed to have a poor prognosis [30]. Our 
previous results showed that FOXC1 was significantly 
upregulated in basal- like specimens as compared to speci-
mens of other molecular subtypes or in normal breast 
tissues [15]. Our current data showed that there was a 
significant correlation between FOXC1 expression levels and 
ERα negative breast cancer and further supported previous 
conclusion. Overexpression of FOXC1 decreased ERα mRNA 
and protein expression. PR (progesterone receptor), IRS1 
(the insulin receptor substrate 1), and XBP1 were consid-
ered as downstream targets of ERα. Expression of PR, 
IRS1, and XBP1 was also reduced when FOXC1 expression 
was increased. In addition, ERE- luc activity was dramati-
cally increased by E2 and the increase was reduced by 
FOXC1 expression. These results suggest that FOXC1 regu-
lated expression of ERα. The recent study also showed 
that FOXC1 was involved in ERα silence [31]. Our primary 
data showed that FOXC1 could bind promoter of ESR1 
(not shown here). The exact mechanism for how FOXC1 
regulated ERα was still not clear and more studies were 
needed to focus on the mechanism in the future. Breast 
cancer cells which expressed ERα are sensitive to E2 stimu-
lation and tamoxifen treatment, such as MCF- 7 and T47D 
cells [6, 32, 33]. The expression of ERα was reduced when 
expression of FOXC1 was increased in MCF- 7- FOXC1 and 
T47D- FOXC1, while expression of ERα was increased when 
expression of FOXC1 was reduced in BT549 FOXC1 shRNA 
and HCC1806 FOXC1 shRNA. This can explain why that 
growth of MCF- 7- FOXC1 and T47D- FOXC1 was not more 
sensitive to E2 than MCF- 7 vector and T47D vector while 
growth of BT549 FOXC1 shRNA and HCC1806 FOXC1 
shRNA was more sensitive to E2 than BT549 vector and 
HCC1806 vector in DMEM (without phenol red) with E2, 
respectively. Similarly, MCF- 7- FOXC1 and T47D- FOXC1 
cells are more insensitive to treatment of tamoxifen than 
MCF- 7 vector and T47D vector, while BT549 FOXC1 shRNA 
and HCC1806 FOXC1 shRNA are more sensitive to treat-
ment of tamoxifen. Therefore, FOXC1 may be used as 
biomarker for treatment in breast cancers by tamoxifen.
Elevated FOXC1 mRNA expression was associated with 
triple- negative breast cancers compared to other hormone 
receptor breast cancer. There is higher FOXC1 expression 
in ERα- negative primary breast cell lines than that in 
ERα- positive primary breast cell lines. Similar situations 
were seen in breast cancer tissues and cell lines. FOXC1 
expression was increased as development of breast cancer. 
These results raise the possibility that FOXC1 and ERα 
coordinately regulate progression of breast cancer.
In summary, our study has firstly reported significant 
correlation between FOXC1 and ERα in breast cancer, which 
might be responsible for the poor progress of triple- negative 
breast cancer in clinic. In addition, it was shown that over-
expression of FOXC1 increased the tumorigenic properties 
of breast cancer cells. Therefore, FOXC1 is possibly to be 
a potential drug target for triple- negative breast cancer.
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Supporting Information
Additional supporting information may be found in the 
online version of this article:
Figure S1. FOXC1 was amplified in invasive breast can-
cer. TCGA data showed that there was 8% FOXC1 
amplification patients in all invasive breast cancer patients 
(8%, 64 in 825).
Figure S2. FOXC1 was negatively correlated with expres-
sion of ERα in breast cancer. (A–E): There was higher FOXC1 
expression in ERα- negative tumors than that in ERα- positive 
tumors. Data and statistics were obtained from www.
oncomine.org (Pollock et al., 2006; Peou et al., 2000; Sorlie 
et al., 2003; Schuetz et al., 2006; Turashvili et al., 2007).
Figure S3. FOXC1 was highly expressed in ERα- negative 
breast cancer. TCGA data showed there was higher FOXC1 
expression in ERα- negative tumors than that in ERα- 
positive tumors.
Figure S4. Expression of ERα mRNA was reduced in 
T47D- FOXC1 cells. (A) FOXC1 mRNA expression in the 
T47D- FOXC1 and T47D vector cells was shown. (B) ERα 
mRNA expression in the T47D- FOXC1 and T47D vector 
cells was shown. Expression of ERα was reduced as FOXC1 
expression was increased.
Figure S5. FOXC1 reduced expression of ERα. (A) 
Expression of ERα and XBP1 was decreased when expres-
sion of FOXC1 was increased in T47D cells. (B) Luciferase 
reporter plasmids containing EREs were transfected into 
T47D cells with or without FOXC1–myc–flag. Estrogen 
treatment can activate ERE- luc luciferase and the activa-
tion can be dramatically reduced by FOXC1 in T47D.
Figure S6. Knockdown of FOXC1 induced expression 
of ERα. (A) Expression of FOXC1 mRNA was significantly 
reduced by two- pair FOXC1 shRNAs in HCC1806 FOXC1 
shRNA. (B) Expression of ERα mRNA was induced when 
expression of FOXC1 was reduced in HCC1806 FOXC1 
shRNA. (C) Protein expression of ERα and XBP1 (down-
stream target of ERα) was increased while protein expres-
sion of FOXC1 and FGF19 (downstream target of FOXC1) 
was reduced in HCC1806 FOXC1 shRNA. D. FOXC1 
shRNA can activate ERE- luc luciferase.
Figure S7. FOXC1 reduced cell response to estrogen 
and tamoxifen. (A) Growth of T47D- FOXC1 was not 
more sensitive to E2 than that of T47D vector. (B) T47D- 
FOXC1 was not more sensitive to treatment of Tamoxifen 
than T47D vector. (C) Growth of HCC1806 FOXC1 shRNA 
was more sensitive to E2 than that of HCC1806 vector. 
(D) HCC1806 FOXC1 shRNA was more sensitive to treat-
ment of Tamoxifen than HCC1806 vector.
Figure S8. FOXC1 was highly expressed in triple- negative 
breast cancer. FOXC1 expression in triple- negative breast 
cancer cells was significantly higher than that in HER 
2- positive and luminal breast cancer cell lines.
Figure S9. FOXC1 was highly expressed in ERα- negative 
tumor. There is higher FOXC1 expression in ERα- negative 
tumors than that in ERα- positive tumors.
Figure S10. FOXC1 expression was increased as devel-
opment of breast cancer. FOXC1 expression was increased 
as the progress of all breast cancer.
